Results 221 to 230 of about 6,793 (233)
Some of the next articles are maybe not open access.
A case of ACTH secreting large cell neuroendocrine carcinoma (LCNEC) of bronchus
Oncology, Gastroenterology and Hepatology Reports, 2012Bronchopulmonary neuroendocrine tumors account for only 20% of all lung carcinomas. These tumors are separated into four subtypes of low-grade (typical carcinoids), intermediate-grade (atypical carcinoids) and high-grade carcinomas which include large cell neuroendocrine carcinoma (LCNEC) and small-cell lung carcinoma (SCLC).
Appalanaidu Sasapu +5 more
openaire +1 more source
Genetic subtypes of large cell neuroendocrine carcinoma (LCNEC) to predict response to chemotherapy.
Journal of Clinical Oncology, 20179061 Background: To treat LCNEC with non-small cell lung carcinoma type chemotherapy (NSCLC-ct, i.e. gemcitabine/taxanes or pemetrexed) or small cell lung carcinoma type (SCLC-ct, i.e. platinum-etoposide) is subject of debate. Molecular studies have identified two mutually exclusive subtypes in LCNEC, the co-mutated TP53 and RB1and the STK11/ KEAP1 ...
Jules Derks +14 more
openaire +1 more source
Journal of Clinical Oncology, 2019
1575 Background: LCNEC and SCLC are aggressive neuroendocrine carcinomas with overlap in clinical, histopathologic, morphologic and genomic features. Differential molecular features between the two subtypes have not been well elucidated, contributing the uncertainty for optimal clinical strategy for each subtype.
Lin Wu +14 more
openaire +1 more source
1575 Background: LCNEC and SCLC are aggressive neuroendocrine carcinomas with overlap in clinical, histopathologic, morphologic and genomic features. Differential molecular features between the two subtypes have not been well elucidated, contributing the uncertainty for optimal clinical strategy for each subtype.
Lin Wu +14 more
openaire +1 more source
Journal of Clinical Oncology, 2014
e19046 Background: LCNEC is a rare thoracic malignancy, for which optimal therapy is not well-defined. We report the largest series of stage IV LCNECs, evaluating clinicopathologic features, treatment and survival outcomes. Methods: Patients (pts) with stage IV LCNEC evaluated at MSKCC from 2006-2013 were identified.
Jarushka Naidoo +8 more
openaire +1 more source
e19046 Background: LCNEC is a rare thoracic malignancy, for which optimal therapy is not well-defined. We report the largest series of stage IV LCNECs, evaluating clinicopathologic features, treatment and survival outcomes. Methods: Patients (pts) with stage IV LCNEC evaluated at MSKCC from 2006-2013 were identified.
Jarushka Naidoo +8 more
openaire +1 more source
Journal of Clinical Oncology
8106 Background: Due to lack of prospective data, the optimal first line treatment approach for patients (pts) with pure LCNEC histology remains uncertain. Methods: Across 17 centers, we conducted a retrospective analysis of metastatic pure LCNEC (diagnosed at local institutions) who received 1st-line systemic therapy between 2015-2023.
Amin Nassar +19 more
openaire +1 more source
8106 Background: Due to lack of prospective data, the optimal first line treatment approach for patients (pts) with pure LCNEC histology remains uncertain. Methods: Across 17 centers, we conducted a retrospective analysis of metastatic pure LCNEC (diagnosed at local institutions) who received 1st-line systemic therapy between 2015-2023.
Amin Nassar +19 more
openaire +1 more source
Large Cell Neuroendocrine Carcinoma (LCNEC) and Lymphoma
2020Jing Feng +4 more
openaire +1 more source
Large-Cell (Undifferentiated) Carcinoma (LCC) Versus Large-Cell Neuroendocrine Carcinoma (LCNEC)
2022Aimi T. Rothrock +2 more
openaire +1 more source
Large cell neuroendocrine carcinoma (LCNEC) harbouring an EML4-ALK rearrangement; case report
Pathology, 2017F. Najdawi, A. Kaufman
openaire +1 more source